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Background: The clinical effectiveness of monovalent influenza A(H1N1)pdm09 vaccines has not been
comprehensively summarised. We undertook a systematic review and meta-analysis to assess vaccine
effectiveness (VE) for adjuvanted and unadjuvanted vaccines.
Methods: We searched healthcare databases and grey literature from 11 June 2009 to 12 November 2014.
Two researchers independently assessed titles and abstracts to identify studies for full review. Random
effects meta-analyses estimated the pooled effect size of vaccination compared to placebo or no vaccina-
tion for crude and adjusted odds ratios (OR) to prevent laboratory confirmed influenza illness (LCI) and
related hospitalization. VE was calculated as (1-pooled OR) ⁄ 100. Narrative synthesis was undertaken
where meta-analysis was not possible.
Results: We identified 9229 studies of which 38 at moderate risk of bias met protocol eligibility criteria;
23 were suitable for meta-analysis. Pooled adjusted VE against LCI with adjuvanted and unadjuvanted
vaccines both reached statistical significance (adjuvanted: VE = 80%; 95% confidence interval [CI] 59–
90%; unadjuvanted: VE = 66%; 95% CI 47–78%); in planned secondary analyses, VE in adults often failed
to reach statistical significance and pooled point estimates were lower than observed in children.
Overall pooled adjusted VE against hospitalization was 61% (95% CI 14–82%); in planned secondary anal-
yses, adjusted VE attained statistical significance in adults aged 18–64 years and children for adjuvanted
vaccines. Adjuvanted vaccines were significantly more effective in children compared to adults for both
outcomes.
Conclusions: Adjuvanted and unadjuvanted monovalent influenza A(H1N1)pdm09 vaccines were both
effective in preventing LCI. Overall, the vaccines were also effective against influenza-related hospitaliza-
tion. For both outcomes adjuvanted vaccines were more effective in children than in adults.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
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The first ever global deployment of pandemic influenza vaccines
was in response to the influenza A(H1N1) pandemic in 2009–10.
Whilst many individual studies have supported the effectiveness
of these vaccines in different populations and geographical areas,
all have been observational designs and several were underpow-
ered or calculated crude estimates of effectiveness without
adjustment for confounding. Two previous systematic reviews
and meta-analyses of 2009–10 vaccine against clinical endpoints
exist, but were conducted too soon following the pandemic to cap-
ture all relevant information [1,2]. Furthermore, Yin et al. did not
calculate adjusted pooled estimates and Osterholm et al. did not
subject their findings to meta-analysis [1,2]. A third systematic
review reported only on serological endpoints [3]. At this point in
time it is unlikely that further novel data on the effectiveness of
monovalent influenza A(H1N1) pdm09 vaccines will be published.
Comprehensive summaries of the available data are required to
inform future public health policies for pandemic vaccine procure-
ment and deployment, and the potential benefits of seasonal influ-
enza vaccination in children. Here we report a systematic review
and meta-analysis, which includes a substantial amount of data
not included in prior meta-analyses, to assess the efficacy and
effectiveness of inactivated monovalent influenza A(H1N1)pdm09
intramuscular vaccines versus placebo or no vaccination to prevent
laboratory confirmed influenza illness (LCI), hospitalization and
mortality due to infections with the vaccinated strain of influenza.
We specified research questions a priori to separately estimate
these outcomes for adjuvanted and unadjuvanted vaccines [4].
Given the reported potential association between narcolepsy and
administration of AS03 adjuvanted monovalent influenza A
(H1N1)pdm09 vaccine, our study may inform the discussion
regarding risk-to-benefit of immunisation [5–8].2. Methods
We followed guidance on Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) [9]. The study protocol
was registeredwith theNational Institute for Health Research inter-
national prospective register of systematic reviews (PROSPERO) [4].2.1. Definitions and outcomes
We defined the study population as people of all ages, from any
setting and included both healthy individuals and those with pre-
existing medical conditions. The interventions of interest were vac-
cination with inactivated adjuvanted or unadjuvanted monovalent
intramuscular vaccines, which contained influenza A/Califor-
nia/7/2009 (H1N1)-like virus. We did not include data on live
attenuated influenza vaccines (LAIV) or multi-valent preparations
which included the pandemic strain. When studies reported using
inactivated vaccine and LAIV in different subjects [10–12], we did
not include the data on LAIV in meta-analyses. Comparator groups
included people who received placebo or who were not vaccinated.
Outcome measures were prevention of reverse transcriptase PCR
(RT-PCR) or viral culture confirmed influenza A(H1N1)pdm09 ill-
ness, hospitalization and mortality. We excluded studies which
only evaluated non-specific outcomes such as influenza-like illness
or all-cause mortality. We assessed experimental and observa-
tional studies and systematic reviews +/ meta-analysis using
the eligibility criteria defined in the study protocol [4].
2.2. Search strategy
Healthcare databases and sources of grey literature were
searched in November 2014 and April 2016 (no new studies iden-
tified) using a pre-specified search strategy considering relevant
papers published from June 2009 and pertaining to the influenza
A(H1N1)pdm09 pandemic period (11 June 2009 to 10 August
2010) [4] (outlined in Supplementary Material). Two reviewers
(LL and SS) independently screened studies for inclusion using a
three-stage sifting approach and extracted data using a piloted
template (see Supplementary Material), referring to CRB or JSN-
V-T for resolution of any discordance.
2.3. Risk of bias assessment
We used the Cochrane Collaboration tool to assess risk of bias in
prospective cohort studies, whilst the Newcastle-Ottawa scale was
used to critique other eligible observational studies in the three
domains of selection of study groups, comparability of the groups
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Fig. 1. PRISMA diagram. Details of the literature search and extraction for the systematic review.
1998 L.E. Lansbury et al. / Vaccine 35 (2017) 1996–2006and ascertainment of outcome [13,14]. Studies of test-negative
design are less prone to bias from misclassification of influenza
and health-seeking behaviour than traditional case-control studies,
but are susceptible to confounding by calendar time [15], particu-
larly during the pandemic when vaccine distribution occurred con-
currently with the second epidemic wave in many countries.
Therefore, we specifically sought evidence of adjustment by calen-
dar time in studies of this design. Systematic reviews meeting the
eligibility criteria were assessed for risk of bias using the US
Agency Healthcare Research Quality domain and element-based
evaluation instrument [16].2.4. Data synthesis
We assessed adjuvanted and unadjuvanted vaccines separately
before combining to give overall estimates of effect. We principally
sought to analyse outcome measures recorded 14 days following
immunisation, in order to allow adequate time for seroconversion.
Secondary sub-group analyses were planned to study outcomes for
clinical risk groups compared to other vaccinated groups, AS03
compared to MF59 adjuvantation, and by age bands (i.e., 0–4, 5–
17, 18–64, and 65 years). Planned sensitivity analyses included
studying outcomes for clinical risk groups, pregnant women,
L.E. Lansbury et al. / Vaccine 35 (2017) 1996–2006 1999healthcare workers, and exploration of potential sources of statis-
tical heterogeneity.
Where appropriate, we estimated the pooled effect size of vac-
cination by random effects model meta-analysis of crude and
adjusted odds ratios (with 95% confidence intervals) for each out-
come measure using the generic inverse variance method in
Review Manager software version 5.3 (Nordic Cochrane Centre,
Cochrane Collaboration, Copenhagen, Denmark). Heterogeneity
was assessed using I2 and meta-analyses were abandoned where
I2 > 85%. The Z test was used to assess if pooled estimates reached
statistical significance at the 5% level. Pooled odds ratios were used
to estimate vaccine effectiveness based on the formula:
VE ð%Þ ¼ ð1 ORÞ  100
Matched studies, which controlled for confounding variables by
design, were pooled with unmatched studies reporting adjusted
ORs. We pooled ORs which adjusted for the largest number of
potential confounders and pooled unadjusted ORs in separate
meta-analyses. We narratively synthesized extracted data not suit-
able for meta-analyses using a recognized framework [17]. Previous
meta-analyses were described but their results were not entered
into our de novo synthesis in order to avoid double-weighting pri-
mary papers included in earlier analyses. Publication bias of studies
included in each meta-analysis was assessed through visual inspec-
tion of funnel plot symmetry (effect size vs sample size) and statis-
tically using Egger’s regression test or Harbord’s modified
regression test using Stata software version 14 (StatCorp LP, Texas,
USA).3. Results
After screening 9229 papers (Fig. 1), 38 studies met the inclu-
sion criteria. Characteristics of the included studies are provided
in the on-line supplementary materials (Supplementary
Table ST1). Data on 7,643,738 individuals from 13 test-negative
design [10,18–29] and 10 traditional case control studies
[11,12,30–37], four retrospective cohorts [38–41], seven prospec-
tive cohorts [42–48], and two screening method studies were
included [49,50]. Two systematic reviews met the eligibility crite-
ria [1,2].
No randomized controlled trials or studies which reported vac-
cine effectiveness against mortality met our eligibility criteria.
Secondary analyses by specific risk groups were not possible due
to inadequate data and varying definitions across studies.
We preferentially report pooled adjusted ORs where possible;
pooled unadjusted ORs are shown in the online supplementary
tables.
3.1. Risk of bias
One systematic review was at moderate or high risk of bias
across most domains [2], whilst the second was at moderate or
low risk (on-line supplementary figure (SF1) [1]. For the seven
prospective cohort studies, most were at high or unclear risk of
bias because of demographic differences between the vaccinated
and unvaccinated cohorts and lack of information about non-
participants (on-line supplementary figure SF2) [42–48]. Nine of
29 outcomes (31%) from 27 case-control and retrospective cohort
studies were at moderate risk of selection bias [11,12,21,30,
32,40,41,49,50]. Since baseline serological assessment was not
undertaken in any of the studies, the inclusion of controls poten-
tially previously infected with influenza A(H1N1)pdm09 is a possi-
ble source of bias. The inherent lack of randomization in
observational studies increases the risk of selection bias. For 86%
of outcomes, cases and non-cases were comparable on the basisof study design or analysis accounting for important potential con-
founding variables Three studies were at unclear risk of bias for
comparability of participant groups [31,49,50], and seven were at
high or very high risk of reporting bias (on-line supplementary
figure SF3) [30–32,35–37,41]. Two studies were not assessed due
to insufficient data [20,34]. Ten of the 13 test-negative design
studies explicitly accounted for calendar time [10,18,21–28]. No
evidence of publication bias was found.
3.2. Laboratory-confirmed influenza A(H1N1)pdm09 illness
Meta-analyses of VE from 14 days after vaccination compared
with non-vaccinated subjects of all ages revealed a pooled point
VE estimate of 80% for adjuvanted vaccines (95% CI 59–90%,
p < 0.00001, I2 = 61%, studies = 4, n = 6361) [18,22,25,26] and 66%
for unadjuvanted vaccines (95% CI 47–78%, p < 0.00001, I2 = 0%,
studies = 3, n = 6876) [10,19,26]. These estimates were not statisti-
cally significantly different. After pooling adjuvanted and unadju-
vanted vaccines we obtained an overall VE of 73% (95%
CI 59–82%, p < 0.00001, I2 = 44%, studies = 7, n = 13,237; Fig. 2).
Studies reporting adjusted VE seven days or more after vaccination
showed that the vaccines were effective at preventing LCI
(VE = 66%, 95% CI 57–74%, p < 0.00001, I2 = 0%, studies = 3,
n = 11,980) [10,18,22]. The results of secondary analyses are sum-
marised in Table 1.
Two earlier systematic reviews (not included in our meta-
analyses) assessed the effect of vaccination on LCI. For adjuvanted
vaccines only, Yin et al. reported crude vaccine effectiveness rang-
ing from 79% (95% CI 22–94%, I2 = 49%) from meta-analysis of two
cohort studies (n = 3149) to 90% (95% CI 25–99%, I2 = 84%) from
meta-analysis of four case control studies (n = 2726) [1]. For unad-
juvanted vaccines, the pooled crude VE estimate was 89% (95% CI
30–98%, I2 = 88%). Osterholm et al. reported a median adjusted
VE of 69% (range 60–93%) from four studies (n = 11,592) [2].
Effect estimates from six studies were not suitable for inclusion
in the meta-analyses and are summarised in on-line supplemen-
tary table ST2 [23,29,38,39,49,50].
3.2.1. Adults 18 years
Neither adjuvanted nor unadjuvanted vaccines showed signifi-
cant effectiveness in adults aged 18 years and over when consid-
ered separately. When both vaccine types were considered
together, vaccine was moderately protective (VE = 49%, 95% CI
13–71%, p = 0.01, I2 = 23%, studies = 5, n = 3979) (Table 1). How-
ever, when two studies at high risk of bias were excluded on sen-
sitivity analysis [19,37], the overall pooled VE point estimate
reduced and became non-significant (VE = 31%, 95% CI 22–61%,
p = 0.2, I2 = 0%, studies = 3, n = 3445) (on-line supplementary table
ST3). Pooled point estimates of unadjusted ORs in adults were
higher than point estimates of adjusted ORs for both adjuvanted
and unadjuvanted vaccines, and reached statistical significance in
all cases (on-line supplementary table ST4). There were no statisti-
cally significant differences between adjuvanted and unadjuvanted
vaccines in adults 18 years.
3.2.2. Adults 50 years
Three studies offered data on VE in adults 50 years [10,18,22].
For studies reporting adjusted outcomes using adjuvanted vaccines
[18,22], the pooled estimated VE was 46% (95% CI 17–75%,
p = 0.22, I2 = 0%, studies = 2, n = 1149). Only one study reported
VE for unadjuvanted vaccine [10]. There was no significant differ-
ence between adjuvanted and unadjuvanted vaccines (p = 0.34).
3.2.3. Children <18 years
Overall pooled adjusted VE in children under 18 years was 76%
(95% CI 48–89%, p = 0.0003, I2 = 50%, studies = 7, n = 3994)
Fig. 2. Forest plot of studies of laboratory-confirmed influenza A(H1N1) pdm09 illness, adjusted ORs, vaccinated versus non-vaccinated persons of all ages, vaccine assumed
to be effective 14 days or more after receipt.
2000 L.E. Lansbury et al. / Vaccine 35 (2017) 1996–2006[10,12,18,19,22,27,28]. Pooled VE was 88% for adjuvanted vaccines
(95% CI 69–95%, p < 0.0001, I2 = 34%, studies = 4, n = 932)
[18,22,27,28], and 45% for unadjuvanted vaccines (95% CI 13–
73%, p = 0.83, I2 = 0%, studies = 3, n = 3062;Fig. 3) [10,12,19]. The
difference between these estimates was statistically significant
(v2 = 6.34, p = 0.01). Restricting the analysis to those studies in
which vaccine effectiveness was assumed from 14 days after vacci-
nation did not affect the overall results with pooled point VE of 73%
(95% CI 35–88%, p = 0.003, I2 = 47%, studies = 5, n = 2272; on-line
supplementary table ST3).
Pooled estimates from unadjusted data [10,12,22,25,28,38,41]
are shown in the on-line supplementary table ST4.
3.2.4. VE in adults 18 years vs. children
Subgroup analysis of VE for adults compared with children was
not statistically significant (v2 = 2.39, p = 0.12; Fig. 4). However,
when considering adjusted outcome data for adjuvanted and unad-
juvanted vaccines separately, subgroup analysis showed adju-
vanted vaccines were significantly more effective in children
than adults (v2 = 7.48, p = 0.0006). For unadjuvanted vaccines,
the difference in VE was not statistically significant.
3.3. Hospitalization due to laboratory-confirmed influenza A(H1N1)
pdm09 illness
Pooling adjusted outcome data on hospitalization 14 days after
vaccination revealed a VE of 61% (95% CI 14–82%, p = 0.02, I2 = 56%,
studies = 3, n = 12,683; Fig. 5) [18,34,36]. For adjuvanted vaccines
the pooled VE was not statistically significant (VE = 82%, 95% CI
110–98%, p = 0.17, I2 = 77%, studies = 2, n = 12,053) [18,34]. Only
one study assessed VE of unadjuvanted vaccine [36].
3.3.1. Adults
For all adults 18 years and above, pooled adjusted VE of adju-
vanted vaccines was 48% (95% CI 35–80%, p = 0.18, I2 = 45%, stud-
ies = 3, n = 1479) [18,21,30].
No significant difference in VE was seen on subgroup analysis of
adjusted data [21,30] for adjuvanted vaccines by adult age groups
(v2 = 0.29, p = 0.59); VE was 78% in adults aged 65 years (95% CI1–95%, p = 0.05, I2 = not applicable, studies = 1, n = 120), and 64% in
adults aged <65 years (95% CI 9–86%, p = 0.03, I2 = 0%, studies = 2,
n = 684) respectively.
3.3.2. Children
Pooled adjusted VE of adjuvanted vaccines in children was 86%
(95% CI 67–94%, p < 0.00001, I2 = 0%, studies = 2, n = 1126) [23,33].
There were no studies of unadjuvanted vaccines with suitable
adjusted data for meta-analysis. Unadjusted data for both vaccine
types are shown in supplementary table ST4.
3.3.3. VE in adults vs. children
Subgroup analysis of adjusted outcome data for studies of adju-
vanted vaccines indicated that these were statistically significantly
more effective at preventing hospitalization in children than adults
(v2 = 4.08, p = 0.04; Fig. 6). There were insufficient adjusted out-
come data to compare age groups for unadjuvanted vaccines.4. Discussion
Overall we found that inactivated monovalent pandemic influ-
enza vaccines were effective in preventing laboratory-confirmed
illness and hospitalization due to A(H1N1)pdm09. Adjuvanted vac-
cines tended to yield higher point estimates of effectiveness,
although superiority was only apparent in children. These findings
are broadly consistent with previous meta-analyses [1,2]. How-
ever, our estimates are generally more conservative, perhaps
reflecting the larger number of studies included and, where possi-
ble, the calculation of pooled adjusted point estimates. We noted
that crude outcome measures tended to produce pooled estimates
of effectiveness that were a magnitude higher than for adjusted
outcome measures. We suggest that data from adjusted outcome
measures are likely to offer more accurate pooled estimates of
effectiveness.
Although monovalent LAIVs were also deployed during the
2009 pandemic (mainly in India, Russia, Thailand and USA) overall
they accounted for <5% of global vaccine production and were not
available in most countries. We therefore have focused on
Table 1
Secondary analyses for pooled vaccine effectiveness against laboratory-confirmed influenza illness (adjusted data).
Subjects Vaccine type Number of participants
(number of datasets) [citation]
VE
(%)*
95% CI (p-value)* I2
(%)
Sensitivity analyses/comments
Laboratory-confirmed influenza illness
Adults (18 years) Adjuvanted 1676(3) [18,22] 40 15 to 68 (p = 0.80) 0
Unadjuvanted 2303(3) [10,19,37] 59 36 to 88 (p = 0.26) 64
All types 3979(6) [10,18,19,22,37] 49 13 to 71 (p = 0.01) 23 No significant difference between adjuvanted and
unadjuvanted vaccines (Χ2 = 0.30, p=0.58).
After exclusion of two studies at high risk of bias:
VE = 31% (95% CI 22–61%), p = 0.20, I2 = 0%
Adults (50 years) Adjuvanted 1149(2) [18,22] 46 17 to 75 (p = 0.12) 0
Unadjuvanted 1859(1) [10] – – – Single study, non-significant result; pooled analysis
not possible: VE = 6% (95% CI 231–66%, p = 0.92)
All types 3008(3) [10,18,22] 33 27 to 65 (p = 0.22) 0 No significant difference between adjuvanted and
unadjuvanted vaccines (Χ2 = 0.92, p = 0.34)
Children
(<18 years)
Adjuvanted >932(4) [18,22,27,28] 88 69 to 95 (p < 0.0001) 34 All AS03 adjuvanted.
Unadjuvanted 3062 (3) [10,12,19] 45 13 to 73 (p = 0.10) 0
All types >3994(7)
[10,12,18,19,22,27,28,]
76 48 to 89 (p = 0.0003) 50 Significant difference in VE between adjuvanted
and unadjuvanted vaccines: Χ2 = 6.34, p = 0.01.
Two included studies reported VE at >10 days and
>7 days respectively. Restricting to those studies in
which vaccine effectiveness was assumed from
14 days after vaccination: VE = 73% (95% CI 35–
88%, p = 0.003, I2 = 47%)
After exclusion of two studies at high risk of bias:
VE = 83% (95% CI 51–94%), p = 0.003, I2 = 63%
Hospitalization due to laboratory-confirmed influenza
Adults (18 years) Adjuvanted 1479(3) [18,21,30] 48 35 to 80 (p = 0.18) 45
Unadjuvanted – – – – No studies
All types n/a n/a n/a n/a All studies reporting adjusted outcomes used
adjuvanted vaccines
Adults  65 years Adjuvanted 120(1) [30] – – – Single study; pooled analysis not possible: VE = 78%
(95% CI 1–95%), p = 0.05
Unadjuvanted – – – – No studies
All types n/a n/a n/a n/a Single study reporting adjusted outcomes used
adjuvanted vaccine
Adults 18–64 years Adjuvanted 684(2) [21,30] 64 9 to 86 (p = 0.03) 0
Unadjuvanted – – – – No studies
All types n/a n/a n/a n/a All studies reporting adjusted outcomes used
adjuvanted vaccines
Children
(<18 years)
Adjuvanted 1136(2) [23,33] 86 67 to 94
(p < 0.00001)
0 Both AS03 adjuvanted.
Unadjuvanted – – – – No studies
All types n/a n/a n/a n/a All studies reporting adjusted outcomes used
adjuvanted vaccines
Table footnotes: Statistically significant results highlighted in bold type.
VE vaccine effectiveness; CI confidence interval.
L.E. Lansbury et al. / Vaccine 35 (2017) 1996–2006 2001inactivated monovalent vaccines which were widely available
[51,52]. We did not consider it appropriate in this meta-analysis
to compare the effectiveness of vaccines administered by different
routes, nor multivalent formulations; data pertaining to these vac-
cine types were explicitly excluded per protocol. The available
studies on intranasal monovalent A(H1N1)pdm09 LAIV have
reported clinical effectiveness against LCI, albeit constrained by
lack of statistical power, broadly in line with our current findings
[10–12,53,54]. It is nonetheless difficult to make a direct compar-
ison due to numerous sources of clinical heterogeneity such as vac-
cine formulation characteristics, antigen components,
comorbidities or sociodemographic differences and prior vaccina-
tion or natural exposure to seasonal influenza A(H1N1)pdm09 con-
ferring cross-protection in populations since the 2009 pandemic
among other factors [55]. In the post-pandemic period, trivalent
or quadrivalent LAIVs incorporating A(H1N1)pdm09 antigens have
been given mainly to children; but their effectiveness against A
(H1N1)pdm09 has been inconsistent, and recently subject to con-
siderable uncertainty [56].
The current study offers important new granularity on the effec-
tiveness of inactivated 2009 pandemic vaccines by age group andvaccine type. These vaccines were more effective in children than
adults and effectiveness was lowest (and non-significant) in recipi-
ents aged >50 years. This trend was observed for laboratory con-
firmed influenza illness and hospitalization. Van Kerkhove and
colleagues have previously described how the prevalence of pre-
existing antibody to A(H1N1)pdm09was sharply aged related, with
a substantially higher level of immunity in people over 50 years of
age [57], (presumably due to previous historical exposure to a sim-
ilar virus), and that the incidence of A(H1N1)pdm09 infection corre-
spondingly declined at this age. Therefore we surmise that
comparisons of vaccinated individuals with non-vaccinated indi-
viduals age >50 years may have been made against a background
of generally high background immunity, biasing our findings in this
age group towards the null and statistical under-powering.
We further explained the overall inverse gradient between
effectiveness and age by comparing adjuvanted versus unadju-
vanted vaccines in each age band. Our results show that adju-
vanted vaccines were significantly more effective in children
than unadjuvanted vaccines in preventing laboratory confirmed
influenza illness by almost a twofold difference in effectiveness.
A similar pattern was also seen for hospitalization. However, in
Fig. 3. Forest plot of studies of laboratory-confirmed influenza A(H1N1) pdm09 illness, adjusted ORs, vaccinated versus non-vaccinated persons in children under 18 years.
Fig. 4. Forest plot of studies of laboratory-confirmed influenza A(H1N1) pdm09 illness, adjusted ORs, adults versus children, adjuvanted and unadjuvanted vaccines.
2002 L.E. Lansbury et al. / Vaccine 35 (2017) 1996–2006adults there were fewer apparent differences between the perfor-
mance of adjuvanted and unadjuvanted vaccines for both out-
comes. The higher effectiveness in children of adjuvanted
vaccines compared to unadjuvanted vaccines noted here has also
been seen in efficacy studies of seasonal trivalent influenza vacci-
nes (TIV) in young children up to 72 months of age, in whom effi-
cacy against PCR-confirmed influenza was 92% for adjuvanted
vaccines versus 45% for unadjuvanted vaccines [58].4.1. Limitations
Although, where possible, we report pooled estimates of
adjusted data to reduce the impact of known confounders on our
pooled point estimates, the included eligible studies were never-
theless non-randomized observational studies, many of which
were judged to have some risk of bias or unclear risk of bias across
most domains. Indeed, exclusion of two studies at high risk of bias
Fig. 5. Forest plot of studies of hospitalization due to laboratory-confirmed A(H1N1)pdm09 illness, adjusted ORs, vaccinated versus unvaccinated persons of all ages, vaccine
assumed to be effective 14 days or more after vaccination.
Fig. 6. Forest plot of studies of hospitalization due to laboratory-confirmed influenza A(H1N1) pdm09 illness, adjusted ORs, adults versus children, all adjuvanted vaccine
studies.
L.E. Lansbury et al. / Vaccine 35 (2017) 1996–2006 2003across two domains changed a significantly protective VE to non-
significant during sensitivity analysis [19,37]. Without randomiza-
tion it is not possible to exclude selection bias. We were unable to
account for prior immunity due to a previous historical exposure to
a closely related virus, asymptomatic infection or mild infection.
Moderate levels of statistical heterogeneity were present in
some meta-analyses, reaching significance in the comparisons of
adjuvanted vaccines in adults and children. Potential confounders
related to prior exposure to influenza viruses, vaccination or partic-
ipant characteristics may be partly responsible. In addition to study
design issues, heterogeneitymay also occur due to real difference in
VE in different populations. Although it was our intention evaluate
vaccine effectiveness in different clinical risk groups lack of data
precluded this. No randomized controlled trials were identified.
Although not an unexpected finding in this scenario, it meant that
we were unable to evaluate the efficacy of the vaccines.
Lack of data limited or prevented some planned analyses.
Although we intended to explore potential differences between
influenza A(H1N1)pdm09 vaccines with AS03 and MF-59 propri-etary adjuvants, we encountered insufficient data to do so, since
almost all studies included used the AS03 adjuvant. Notwithstand-
ing we have pooled these adjuvanted studies for our analysis and
believe this is rational based on the fact that both are ‘same-
class’ squalene-based, oil-in-water, adjuvants. Analysis of the
effect of giving a scheduled second dose of vaccine was precluded
due to the low number of people who received more than one dose
in the relevant studies.4.2. Implications for public health policy
Our results establish that influenza A(H1N1)pdm09 vaccines
produced globally in response to the 2009–10 pandemic were
broadly effective in reducing influenza illness and hospitalization.
For the time being, the potential impact on mortality remains an
assumption or derivation in future pandemic planning, as this
potential benefit is currently unsupported by existing scientific
evidence.
2004 L.E. Lansbury et al. / Vaccine 35 (2017) 1996–2006The findings need to be placed in the context that the A(H1N1)
pdm09 virus emerged in March–April 2009 but vaccine was not
available for widespread distribution until October 2009, during
the second pandemic wave, owing to the lead times in production.
Although highly successful in averting cases of influenza, vaccines
would have achieved a far greater public health impact if their arri-
val had been a fewmonths sooner [59,60]. There remains a joint sci-
entific, regulatory, and public health imperative to streamline the
process of triggering pandemic vaccine production and decrease
production lead times, whilst simultaneously pursuing opportuni-
ties to develop a ‘universal’ influenza vaccine, as endorsed in the
WHO Pandemic Influenza Preparedness Framework [61].
Since pandemic planning gathered momentum in 2003 until
2009, health authorities focused mainly on the potential pandemic
threat posed by avian influenza A(H5N1). It is widely recognized
that human vaccines targeted against this subtype are relatively
poorly immunogenic, and that in general two doses are required
for adequate seroconversion [62]. This was generally not the case
with A(H1N1)pdm09 vaccines [63]. The data we have generated
may constitute important knowledge if a future pandemic virus
necessitates two doses to confer clinical protection and antigen
sparing strategies involving the use of adjuvants are required to
achieve rapid population coverage.
Evidence from modeling studies suggests that children are a
credible target group for pandemic vaccination, along with
patients who have high-risk conditions [64–66]. This assertion is
now supported for seasonal influenza by data from the UK child-
hood influenza vaccination programme [67]. Since there is evi-
dence from our meta-analyses that adjuvanted vaccines were
more effective in children than unadjuvanted vaccines and given
that antigen sparing strategies may be critically important during
a future pandemic [68], this draws the current narcolepsy signal
associated with AS03-containing influenza vaccines into sharp
relief in the context of a potentially altered risk-benefit profile dur-
ing a more severe pandemic [69]. Efforts to study expansion of
adjuvanted vaccines in paediatric populations for seasonal use
are warranted, both to improve prevention of seasonal influenza,
and potentially to expedite potential use of adjuvanted vaccines
during a future pandemic.
5. Conclusion
Through a comprehensive global systematic review and meta-
analysis, we have identified that inactivated monovalent A
(H1N1)pdm09 vaccines were effective in preventing laboratory-
confirmed influenza illness and related hospitalization. In children,
adjuvanted vaccines were more effective than unadjuvanted
vaccines.
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